Phase II Trial of cdk Inhibitor SCH 727965 in Multiple Myeloma (P2C MC0888, NCI 8288).
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2014
At a glance
- Drugs Dinaciclib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 10 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Feb 2013 New source identified and integrated (Mayo Clinic: 08-004470)
- 19 Dec 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.